Por: The Daily Beast World November 20, 2022
With evolving faster and faster, each chipping away at the effectiveness of the leading , the hunt is on for a new kind of vaccine—one that works equally well on current and future forms of the novel-coronavirus.Now researchers at the National Institutes of Health in Maryland think they’ve found a new approach to vaccine-design that could lead them to a long-lasting jab. As a bonus, it also might work on , not just the SARS-CoV-2 virus that... + full article
ABC News USA Health November 04, 2022
Pfizer and BioNTech have launched a clinical trial on a vaccine targeting both COVID-19 and influenza, the companies Thursday.The phase 1 trial is being done in the United States with 180 participants between the ages of 18 and 64, with the first participant dosed this week, the... + más
Moderna sues Pfizer over patents behind COVID-19 vaccine | The Advocate
Moderna is suing Pfizer over its coronavirus vaccine | The Verge
ABC News USA Life November 01, 2022
After decades of researching respiratory syncytial virus, an , scientists this week announced a major development in plans for a possible vaccine that could be available as soon as next year.Among very young children, particularly those [younger] than 6 months of age, we have a... + más
After promising trial results for maternal RSV vaccine, Pfizer says it will seek FDA approval this year | CNN
Strong RSV vaccine data lifts hopes after years of futility | 10 WBNS
CNN USA Health October 19, 2022
CNN — The US Food and Drug Administration on Wednesday among adults 18 and older, at least six months after completing a primary Covid-19 vaccine series. The company announced that it has received emergency use authorization to provide a first booster dose of its vaccine... + más
FDA authorizes Novavax's Covid shots as mix-and-match booster to Pfizer or Moderna | CNBC
US clears Novavax COVID booster dose | ABC News
ABC7 USA Health October 18, 2022
in an interview over the weekend. Her husband, professor Ugur Sahin, with whom she cofounded the German pharmaceutical company BioNTech, said he thought cancer vaccines could be widely available before 2030.The husband-and-wife duo founded BioNTech in 2008 originally to develop... + más
Cancer vaccine may be ready by 2030, say founders of COVID vaccine makers BioNTech | ABC News
In Boston visit, BioNTech’s leaders say the pandemic isn’t close to being over | The Boston Globe
ABC News USA World October 18, 2022
LONDON -- The world could be only a few years away from a cancer vaccine, according to the couple behind the Pfizer/BioNtech COVID-19 vaccine.We feel that a cure for cancer or to changing cancer patients' lives is in our grasp, professor Ozlem Tureci told in an interview... + más
Cancer vaccine may be ready by 2030, say founders of COVID vaccine-makers BioNTech | ABC7
The Daily Beast USA Politics September 28, 2022
Patients who have been vaccinated against the monkeypox virus were 14 times less likely to become infected than those who had not been vaccinated, according to initial data released by the Centers for Disease Control and Prevention on Wednesday, which public health officials say... + más
HIV-positive people who have monkeypox are hospitalized more often, CDC study says | CNBC
Los Angeles health officials are investigating the death of a person who had monkeypox | CNBC
RTTNews USA Health September 24, 2022
Getting an updated Covid vaccine this fall will help restore protection that has waned since previous vaccination, according to the White House Covid-19 Response Team.Laboratory data suggests that the addition of the Omicron BA.4 and BA.5 spike protein components may help... + más
Pfizer, BioNTech ask FDA to approve updated COVID booster for ages 5-11 | WPTV
US officially added to WHO’s list of poliovirus outbreak countries | Ars Technica
About iurex | Privacy Policy | Disclaimer |